Literature DB >> 2839745

Percutaneous, in vivo excimer laser angioplasty: results in two experimental animal models.

J M Isner1, D Gal, P G Steg, S T DeJesus, A J Rongione, K R Halaburka, G A Slovenkai, R H Clarke.   

Abstract

Pulsed ultraviolet light from an excimer laser was successfully transmitted via conventional fused silica optical fibers and used to accomplish recanalization of stenotic or totally occluded arteries in an intact, flowing blood field of two atherosclerotic animal models. The fibers, 300-600 micron in diameter, were delivered percutaneously in wire-guided multilumen catheters and then used to transmit wavelengths of 308 or 351 nm from excimer lasers with pulse durations of 12 nsec or less. Lesions from 70-100% diameter narrowing, and 0.6 to 5.5 cm in length were successfully recanalized (less than 50% residual diameter narrowing) in eight animals, using 3-4 J/cm2/pulse, 10-50 Hz, and 48-370-sec cumulative exposure. Necropsy examination in six of the eight animals disclosed no signs of thermal injury. Perforations were observed in four of eight animals. Thus, while use of an excimer laser power source did not obviate vascular perforation as a complication of laser angioplasty, these preliminary results indicate that energies of pulsed ultraviolet light sufficient to ablate atherosclerotic plaque can be both transmitted via conventional fused silica optical fibers and used successfully within an intact, flowing blood field. It may therefore be possible to use pulsed ultraviolet light from an excimer laser to accomplish percutaneous ablation of atherosclerotic arterial obstructions in humans.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839745     DOI: 10.1002/lsm.1900080302

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  1 in total

1.  Animal evaluation of the prototype omnicath atherectomy catheter.

Authors:  M R Sapoval; J C Gaux; P Bruneval; P Peronneau
Journal:  Cardiovasc Intervent Radiol       Date:  1994 Jul-Aug       Impact factor: 2.740

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.